Calliditas Therapeutics AB (FRA:LC8A) Stock News, Headlines & Updates
Calliditas Therapeutics AB Stock News from GuruFocus
- 1
Jun 18, 2024
Calliditas provides setanaxib patent update
PRNewswire • 6:00am
Jun 17, 2024
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
PRNewswire • 12:00pm
Jun 07, 2024
Kuehn Law Encourages CALT, AKLI, AGR, and SGE Investors to Contact Law Firm
Marketwired • 11:00am
Jun 05, 2024
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB -- CALT
Marketwired • 2:00pm
STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALT
PRNewswire • 7:00pm
Jun 04, 2024
SHAREHOLDER UPDATE: Halper Sadeh LLC Continues to Investigate OSG, IBTX, CALT, SSB
PRNewswire • 7:00pm
May 30, 2024
Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy
PRNewswire • 2:00pm
May 28, 2024
Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress
PRNewswire • 8:00am
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders
Business Wire • 8:00am
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
PRNewswire • 3:00am
May 24, 2024
Q1 2024 Calliditas Therapeutics AB Earnings Call Transcript
GuruFocus Research • 11:06am
May 23, 2024
Calliditas Q1 report, January - March 2024
PRNewswire • 1:00am
May 16, 2024
In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action
PRNewswire • 11:00am
Invitation to the presentation of Calliditas´s interim report January - March 2024
PRNewswire • 2:00am
May 15, 2024
Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm
PRNewswire • 8:00am
May 14, 2024
Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China
PRNewswire • 7:00am
May 06, 2024
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
PRNewswire • 2:00am
Apr 24, 2024
Calliditas Therapeutics' 2023 Annual Report Published
PRNewswire • 1:00pm
Calliditas Announces Positive NefIgArd Open Label Extension Results
PRNewswire • 3:00am
Apr 18, 2024
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
PRNewswire • 7:00am
Apr 09, 2024
Calliditas Therapeutics to Attend Conferences in April
PRNewswire • 7:00am
Apr 08, 2024
- 1
Show
Entries
Headlines
Total 0- 1
No recent news